"Estimated theoretical benefit of aggressive LDL lowering in patients w" by James Ernest Siegler, Elena Badillo Goicoechea et al.
 

Estimated theoretical benefit of aggressive LDL lowering in patients with symptomatic intracranial atherosclerosis

Authors

James Ernest Siegler, Department of Neurology, University of Chicago, IL.
Elena Badillo Goicoechea, Biological Sciences Division, University of Chicago, IL.
Shadi Yaghi, Department of Neurology, Brown University, Providence, RI.
Rami Z. Morsi, Department of Neurology, University of Chicago, IL.
Andrea Arevalo, Department of Neurology, University of Chicago, IL.
Matthew M. Smith, Department of Neurology, University of Chicago, IL.
Sachin Kothari, Department of Neurology, University of Chicago, IL.
Harsh Desai, Department of Neurology, University of Chicago, IL.
Neha Sehgal, Department of Neurology, University of Chicago, IL.
Rohini Rana, Department of Neurology, University of Chicago, IL.
Caroline Alice Kellogg, Department of Neurology, Brown University, Providence, RI.
Aditya Jhaveri, Department of Neurology, University of Chicago, IL.
Adam de Havenon, Department of Neurology, Yale School of Medicine, New Haven, CT.
Therese Dunne, Advocate Health - MidwestFollow
Kamil Cameron, Delaware State University, Dover.
Seemant Chaturvedi, Department of Neurology, University of Maryland, Baltimore; and.
Malik Ghannam, Department of Neurology, University of Iowa, Iowa City.
Shyam Prabhakaran, Department of Neurology, University of Chicago, IL.
Elisheva Coleman, Department of Neurology, University of Chicago, IL.
James R. Brorson, Department of Neurology, University of Chicago, IL.
Rachel Mehendale, Department of Neurology, University of Chicago, IL.
Tareq Kass-Hout, Department of Neurology, University of Chicago, IL.

Affiliations

Advocate Lutheran General Hospital

Abstract

Objectives:Given the high risk of recurrent atherosclerotic vascular events in patients with stroke due to intracranial atherosclerotic disease (ICAD), we estimated the potential benefit of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in this population.

Methods:In this secondary analysis of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial, we estimated the association between 30-day low-density lipoprotein (LDL) reduction and recurrent stroke or myocardial infarction (MI) beyond 30 days (primary outcome). Estimates were assessed using adjusted Cox proportional hazards regression. We applied relative LDL reduction estimates from PCSK9i trials to project adjusted incidence rate differences of the primary outcome with an equivalent LDL reduction.

Results:Of the 451 patients from SAMMPRIS, 378 met inclusion criteria. In adjusted Cox regression, every 10 mg/dL LDL improvement was associated with a 9% lower rate of the primary outcome (adjusted hazard ratio 0.91, 95% CI 0.83-0.997). Assuming an average projected effect of PCSK9i, estimating if half of SAMMPRIS patients were treated, PCSK9i use could reduce the annualized risk of the primary outcome by 33.2% in this trial population.

Discussion:Every 10 mg/dL reduction in LDL for patients with stroke due to ICAD is associated with lower rates of recurrent stroke or MI, and this theoretical framework suggests that PCSK9i can help achieve this goal.

Trial registration information:Secondary analysis of NCT00576693 prospectively registered interventional clinical trial. First registered December 7, 2007. Actual study start date: October 2008. https://clinicaltrials.gov/show/NCT00576693.

Classification of evidence:This study provides Class IV evidence that a higher absolute reduction in LDL was associated with a lower risk of recurrent cerebral infarction or MI in patients with recent stroke due to intracranial stenosis.

Document Type

Article

PubMed ID

40446174


 

Share

COinS